Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0434 • ACR Convergence 2025
The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice
Katarina Friberger Pajalic¹, Jon Einarsson¹, Caroline Bengtsson², Elisabeth Mogard³, Ellen Landgren⁴, Carmen Roseman³, Elisabet Lindqvist³, Johan Karlsson Wallman⁵, Tor Olofsson⁶ and Meliha Kapetanovic³, ¹Lunds University, Department of clinical sciences, section of Rheumatology Malmö and Skåne University Hospital Malmö, Sweden, Lund, Sweden, ²Skåne University Hospital Lund, Sweden, Lund, Sweden, ³Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, ⁴Lunds University, Department of clinical sciences, section of Rheumatology, Lund, Skane Lan, Sweden, ⁵Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ⁶Lunds University, Department of clinical sciences, section of Rheumatology, Lund, Sweden
Background/Purpose: Since 2021, patients with new-onset rheumatoid arthritis (RA) at the Department of Rheumatology, Skåne University Hospital, Lund, Sweden, are invited to participate in a…
Abstract Number: 0274 • ACR Convergence 2025
Transplant-free survival in patients with systemic autoimmune rheumatic diseases and progressive pulmonary fibrosis in the ILD-PRO Registry
Sonali Bracken¹, Aparna Swaminathan², Jeremy M Weber³, Megan L Neely⁴, Scott Palmer⁴, Erin Wilfong⁵, Ann Chauffe⁶ and Elizabeth Volkmann⁷, ¹Duke University Medical Center, Durham, NC, USA, Apex, NC, ²Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, USA, Durham, ⁴Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA, Durham, ⁵Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Progressive pulmonary fibrosis (PPF) is known to be associated with high mortality, but there are few data on the course of PPF in patients…
Abstract Number: 0170 • ACR Convergence 2025
Rheumatoid arthritis, serologic status and risk of heart failure: A national cohort study
Seonyoung Kang¹, Kyungdo Han², Yeonghee Eun³, Jinhyung Jung⁴, Seulkee Lee¹, Hoon-Suk Cha¹, Jaejoon Lee⁵, Seonghye Kim¹, Se Yun Kim⁶, Dong Wook Shin¹ and Hyungjin Kim⁷, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Soongsil University, Seoul, Republic of Korea, ³Kangbuk Samsung Hospital, seoul, Republic of Korea, ⁴Sungkyunkwan University School of Medicine, Suwon, Republic of Korea, ⁵Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁶Sungkyunkwan University, Seoul, Republic of Korea, ⁷Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Although rheumatoid arthritis (RA) is a known risk factor for heart failure (HF), a limited number of studies has explored the association based on…
Abstract Number: 0089 • ACR Convergence 2025
Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis
Maria-Eugenia Miranda-Carus¹, Mariana Gutierrez-Riart², Beatriz Nieto-Carvalhal³, Laura Nuño², Alejandro Villalba¹, Diana Peiteado¹, Irene Monjo Henry¹, Marta Novella-Navarro¹ and Eugenio de Miguel¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, ³Hospital Universitario La Paz, Mdrid
Background/Purpose: Subjects with clinically suspect arthralgia (CSA) are at risk for developing rheumatoid arthritis (RA) and therapeutic interventions may prevent or delay progression. Still, a…
Abstract Number: 0070 • ACR Convergence 2025
Integrating Synovial Protein Signatures and Serum Profiles to Predict Disease Activity and Treatment Response in Early Rheumatoid Arthritis
Chary López pedrera¹, Sagrario Corrales², Julio Osuna³, Rafaela Ortega-Castro⁴, Jerusalén Calvo⁵, Lourdes Ladehesa⁶, Ismael Sanchez-Pareja², Laura muñoz-Barrera², Desiree Ruiz-Vilchez⁷, Christian Merlo⁸, MARIA ANGELES AGUIRRE ZAMORANO², Nuria Barbarroja⁹, Tomás Cerdó², Marta Alarcon-Riquelme¹⁰, Carlos Pérez Sánchez¹¹, Alejandro Escudero Contreras⁵ and Concepción Aranda-Valera⁵, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Spain., Córdoba, Republic of Korea, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁵IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ⁸Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁰Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The analysis of synovial tissue has been instrumental in advancing our understanding of Rheumatoid Arthritis (RA) pathogenesis. As an alternative, the identification of serum…
Abstract Number: 0045 • ACR Convergence 2025
Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
Thomas Riley¹, Bryant England², Austin Wheeler², Punyasha Roul³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Mitchell Lazar¹, Wenxiang Hu¹⁴, Michael Levin¹⁵, Scott Damrauer¹⁵, Rui Xiao¹⁶, Tate Johnson², Ted Mikuls², Joshua Baker¹ and Michael George¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴Guangzhou National Laboratory, Guangzhou, China (People's Republic), ¹⁵University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ¹⁶Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Previous studies identified single nucleotide polymorphisms (SNPs) that affect hepatocyte and adipocyte response to glucocorticoids (GCs). We aimed to determine if these candidate SNPs…
Abstract Number: 2643 • ACR Convergence 2025
Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy
Rahul Bodkhe¹, Kai Trepka¹, Diego Orellana¹, Rebecca Blank², Peter Turnbaugh³, Jose Scher⁴ and Renuka Nayak⁵, ¹University of California San Francisco, San Francisco, CA, ²NYU Langone Health, New York, NY, ³University of California, San Francisco, San Francisco, CA, ⁴New York University School of Medicine, New York, NY, ⁵University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a common systemic autoimmune disease that targets the joints, causing persistent pain and swelling. Oral methotrexate (MTX) remains first-line therapy…
Abstract Number: 2419 • ACR Convergence 2025
Dried Blood Spots for Remote ANA and Autoantibody Screening
Miriam Li¹, Paul Sciore², Marvin J. Fritzler³, Ashley Clarke¹, Wrechelle Ocampo¹, katherine Buhler¹, Jeremiah Seni⁴, Lynden Crowshoe¹, Dianne Mosher¹ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²MitogenDx, Calgary, AB, Canada, ³MitognDx, Calgary, AB, Canada, ⁴Catholic University of Health and Allied Sciences, Mwanza, Tanzania
Background/Purpose: Antinuclear antibody (ANA) and SLE-related autoantibody testing are integral parts of SLE screening, diagnosis, and monitoring. However, these tests rely on access to phlebotomy…
Abstract Number: 2276 • ACR Convergence 2025
Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
Jennifer Hanberg¹, David Cheng², Xuan Wang³, Rahul Sangar⁴, Yuk-Lam Ho⁴, Lauren Costa⁴, Rachael Matty⁴, Candace Feldman¹, Tate Johnson⁵, Joshua Baker⁶, Bryant England⁵, J. Michael Gaziano¹, Kelly Cho⁷, James O'Dell⁵, Grant Cannon⁸, Paul Monach⁴, Ted Mikuls⁵, Tianxi Cai⁷ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³University of Utah, Salt Lake City, UT, ⁴VA Boston Healthcare System, Boston, MA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Harvard Medical School, Boston, MA, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are often avoided when treating rheumatoid arthritis (RA) patients with decompensated heart failure (HF), based on increased rates of…
Abstract Number: 2261 • ACR Convergence 2025
Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India
Sryla Punjadath¹, Venkatesh Srinivasa Pai¹, Prativa Priyadarshani Sethi¹, ritu sangwan², Abhishek Rai³ and Ravi Kant¹, ¹All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, ²AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, ³AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India
Background/Purpose: Palindromic Rheumatism (PR) is recognized as a clinical syndrome of intermittent episodes of pain, swelling, and erythema in and around joints, which are severe…
Abstract Number: 2244 • ACR Convergence 2025
Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling
Kei Hirose¹, Keigo Hayashi², Natsuki Kubota², Yuya Terajima², Kazuya Matsumoto², Takato Nakadoi², Shoichi Nawachi², Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama², Haruki Watanabe², Mariko Narazaki², Yoshinori Matsumoto² and Jun Wada², ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a well-established risk factor for fractures, due to both systemic inflammation and treatment-related effects on bone metabolism. This study aimed…
Abstract Number: 2228 • ACR Convergence 2025
COVID-19 Outcomes in Rheumatoid Arthritis Patients Prescribed Biologic vs. Conventional DMARDs: A Propensity-Matched Analysis
Chase Verdugo¹, Yazin Hindosh¹, Akram Hindosh¹, Jonathan Sayegh¹, Bassam Mitri¹, Johnny Youssef¹, Tyler On¹, Faissal Stipho² and Issa Batarseh², ¹University of Arizona College of Medicine Tucson, Tucson, AZ, ²Department of Internal Medicine, Banner University Medical Center / University of Arizona, Tucson, Arizona, Tucson, AZ
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by immune system dysregulation, and it is commonly treated with either conventional or biologic Disease-Modifying Antirheumatic…
Abstract Number: 1957 • ACR Convergence 2025
Correlates Between Cardiovascular Risk Scores with Coronary Microvascular Function and Plaque Burden in Rheumatoid Arthritis
Katherine Zhong¹, Lauren rusnak², Ying Qi³, Ilana Usiskin⁴, Gregory McDermott⁵, Brittany Weber⁶, Marcelo DiCarli⁵ and Katherine Liao², ¹Brigham and Women's Hospital, Short Hills, NJ, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, ⁴Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: A combination of traditional risk factors and chronic inflammation account for the excess cardiovascular risk (CV) observed in rheumatoid arthritis (RA), including atherosclerotic cardiovascular…
Abstract Number: 1890 • ACR Convergence 2025
Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021
Eva Kalra¹, Shreyaa Rajpal², Twisha Parikh³, Drumadala Gajbhiye⁴, Chethan Raj Gundoji⁵, Sagar Patel⁶, Jay Patel⁷, Neelima Sinha⁸, Nikhil Rayarakula⁹, Dhwani Vaghani¹⁰ and Hardik Dineshbhai Desai¹¹, ¹Trident Medical Center, North Charleston, SC, ²Osmania Medical College, Hyderabad, Telangana, India-⁵⁰⁰⁰⁹⁵, Hyderabad, India, ³GMERS Medical College and Hospital, Gotri, Vadodara, India ³⁹⁰⁰²¹, Vadodara, India, ⁴Government medical college Akola Maharashtra India ⁴⁴⁴⁰⁰¹, Akola, India, ⁵Internal Medicine, Government Medical College Nizamabad, Nizamabad, Telangana, India, ⁵⁰³⁰⁰¹, Nizamabad, India, ⁶Internal medicine -Ward Wizard Medicare Pvt Ltd, Nadiad, Gujarat, India, ³⁸⁷⁰⁰², Nadiad, India, ⁷MGM Medical College, Aurangabad, Maharashtra, India-⁴³¹⁰⁰³, Aurangabad, India, ⁸Department of Medicine, Kurji Holy Family Hospital, Patna, Bihar, India, ⁸⁰⁰⁰¹⁰, Patna, India, ⁹College of Public Health, Kent State University, Kent,Ohio, USA, ⁴⁴²⁴²., Kent, OH, ¹⁰Internal Medicine, MGM Medical College, Aurangabad, Maharashtra, India,⁴³¹⁰⁰³, Aurangabad, India, ¹¹Ahmedabad, Gujarat, India, ³⁸²³⁵⁰, Ahmedabad, India
Background/Purpose: Rheumatoid arthritis (RA), a chronic systemic inflammatory disorder, imposes a significant global health burden. Smoking is a well-established modifiable risk factor implicated in both…
Abstract Number: 1724 • ACR Convergence 2025
Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis.
Manon LESTURGIE-TALAREK¹, Virginie Gonzalez², Anne Cauvet², Lucie Beaudoin³, Fiona Oudart⁴, Adrien Schvartz⁵, Francesco Carbone⁵, Mickael Menager⁵, Noémie Sénot³, Francoise Tilotta⁶, Yannick Allanore⁷, Agnes Lehuen⁸ and Jérôme AVOUAC⁹, ¹Paris University, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Institut Cochin, Paris, ⁴APHP - Cochin hospital, Paris, France, ⁵Institut Imagine, Paris, ⁶Université Paris Cité, Montrouge, France, ⁷Université Paris Cité, Paris, France, ⁸Hôpital Cochin, Paris, France, ⁹Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that produce cytokines and cytotoxic molecules. Reduced frequencies and altered phenotypes of MAIT cells have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].